UBS AM
HRTX icon

UBS AM’s Heron Therapeutics HRTX Stock Holding History

UBS AM’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$887 Hold
2,078
– – ﹤0.01% 3623
2026
Q1 		$1.66K Buy
+2,078
New +$2.41K ﹤0.01% 3627
2023
Q3 		– Sell
-110,752
Closed -$167K – 2636
2023
Q2 		$167K Hold
110,752
– – ﹤0.01% 2592
2023
Q1 		$167K Hold
110,752
– – ﹤0.01% 2592
2022
Q4 		$277K Hold
110,752
– – ﹤0.01% 2356
2022
Q3 		$467K Hold
110,752
– – ﹤0.01% 2369
2022
Q2 		$309K Hold
110,752
– – ﹤0.01% 2474
2022
Q1 		$634K Sell
110,752
-256
-0.2% -$1.87K ﹤0.01% 2369
2021
Q4 		$1.01M Buy
111,008
+13,069
+13% +$133K ﹤0.01% 2206
2021
Q3 		$1.05M Sell
97,939
-5,441
-5% -$66.2K ﹤0.01% 2141
2021
Q2 		$1.6M Buy
103,380
+4,811
+5% +$76.5K ﹤0.01% 1956
2021
Q1 		$1.6M Buy
98,569
+4,171
+4% +$74.4K ﹤0.01% 1850
2020
Q4 		$2M Hold
94,398
– – ﹤0.01% 1686
2020
Q3 		$1.4M Buy
94,398
+4,274
+5% +$66.7K ﹤0.01% 1697
2020
Q2 		$1.33M Sell
90,124
-918
-1% -$15.1K ﹤0.01% 1682
2020
Q1 		$1.07M Sell
91,042
-93
-0.1% -$1.75K ﹤0.01% 1670
2019
Q4 		$2.14M Buy
91,135
+1,988
+2% +$44K ﹤0.01% 1578
2019
Q3 		$1.65M Buy
89,147
+23,288
+35% +$429K ﹤0.01% 1702
2019
Q2 		$1.22M Buy
65,859
+8,280
+14% +$165K ﹤0.01% 1802
2019
Q1 		$1.41M Buy
57,579
+9,551
+20% +$250K ﹤0.01% 1680
2018
Q4 		$1.25M Buy
48,028
+8,248
+21% +$227K ﹤0.01% 1653
2018
Q3 		$1.26M Buy
39,780
+5,710
+17% +$213K ﹤0.01% 1715
2018
Q2 		$1.32M Buy
34,070
+7,967
+31% +$254K ﹤0.01% 1702
2018
Q1 		$720K Buy
26,103
+13,403
+106% +$304K ﹤0.01% 1882
2017
Q4 		$230K Buy
+12,700
New +$207K ﹤0.01% 2238
2016
Q4 		– Sell
-15,200
Closed -$262K – 2561
2016
Q3 		$262K Hold
15,200
– – ﹤0.01% 2336
2016
Q2 		$274K Hold
15,200
– – ﹤0.01% 2266
2016
Q1 		$289K Hold
15,200
– – ﹤0.01% 2233
2015
Q4 		$406K Buy
+15,200
New +$406K ﹤0.01% 2167

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

UBS AM's HRTX Position: Q2 2026 in Review

UBS AM held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 2,078 shares worth $887. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

UBS AM first reported a position in HRTX in Q4 2015 and has held it in 29 quarters since. The position peaked at $2.14M in Q4 2019. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • UBS AM held 2,078 shares of Heron Therapeutics worth $887 as of Q2 2026.
  • UBS AM left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3623 holding.
  • UBS AM first reported a position in Heron Therapeutics in Q4 2015 and has held it in 29 quarters since.
  • UBS AM's Heron Therapeutics position peaked at $2.14M in Q4 2019.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.